SCHEMBL5467129

SCHEMBL5467129

NC(=O)c1c(NC(=O)Nc2ccc(OCc3ccccc3)cc2)sc2c1CCSC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 1/20 0.50
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
NOX1 Q9Y5S8 2/20 0.47
KCNH2 Q12809 6/20 0.46
FLT3 P36888 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LTA4H P09960 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
EPHB4 P54760 1/20 0.45
THRB P10828 1/20 0.45
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458514 0.88 FLT3 (0.61) TNIKFLT3NPC1RAB9AMEN1
SCHEMBL5451378 0.88 TNIK (0.52) TNIKCA12CA1CA2CA9
SCHEMBL5465704 0.84 NPC1 (0.51) TNIKCA12CA1CA2CA9
SCHEMBL5451654 0.84 TNIK (0.54) TNIKKCNH2FLT3NPC1RAB9A
SCHEMBL5453159 0.83 FLT3 (0.55) TNIKKCNH2FLT3NPC1RAB9A
SCHEMBL5463075 0.80 FLT3 (0.53) TNIKFLT3NPC1RAB9AMEN1
SCHEMBL5455850 0.80 FLT3 (0.53) TNIKKCNH2FLT3NPC1RAB9A
SCHEMBL5452256 0.80 TLR2 (0.53) TNIKKCNH2FLT3NPC1RAB9A
SCHEMBL5447105 0.80 KMT2A (0.58) TNIKKCNH2NPC1RAB9AMEN1
SCHEMBL5457467 0.78 FLT3 (0.56) TNIKKCNH2FLT3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 TNIK 4134/4885CA12 4783/4885CA1 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.